Finox :: Biotech

Our Biosimilars are different

VISION - our Biosimilars are positively differentiated compared to the reference product both by a particularly attractive pricing strategy and by an innovative injection technology.

MISSION - we develop Biosimilars with the aim of being "first-to-market". This ensures an advantageous position over subsequent competitor products.

ORGANISATION - we develop our Biosimilars from molecule-to-market using an established network of partners.

TARGET MARKETS - our focus is on first approvals in Europe and North America, followed by a global marketing.

PIPELINE - FINOX's first biosimilar is an r-hFSH, a recombinant human follicle-stimulating hormone. This is being developed under the brand AFOLIA^TM and is currently in clinical Phase III testing.

In parallel, we are evaluating further development candidates.


	CORPORATE BIOTECH Afolia DEVICE TECHNOLOGY EN \| DE Our Biosimilars are different VISION - our Biosimilars are positively differentiated compared to the reference product both by a particularly attractive pricing strategy and by an innovative injection technology. MISSION - we develop Biosimilars with the aim of being "first-to-market". This ensures an advantageous position over subsequent competitor products. ORGANISATION - we develop our Biosimilars from molecule-to-market using an established network of partners. TARGET MARKETS - our focus is on first approvals in Europe and North America, followed by a global marketing. PIPELINE - FINOX's first biosimilar is an r-hFSH, a recombinant human follicle-stimulating hormone. This is being developed under the brand AFOLIA^TM and is currently in clinical Phase III testing. In parallel, we are evaluating further development candidates.